| Methods |
RCT.
Observer masked.
Active controlled. |
| Participants |
189 people with POAG.
Racial constitution is not reported.
Inclusion criteria: IOP 22 mmHg or greater, visual field defect in SAP.
Exclusion criteria: history of severe ocular trauma or intraocular surgery, ocular infection within 3 months before study start, concomitant medication known to affect IOP. |
| Interventions |
Timolol 0.25% or 0.5% twice daily (adjustment according to IOP).
Pilocarpine 2% or 4% twice daily (adjustment according to IOP). |
| Outcomes |
Change of visual field mean sensitivity.
IOP. |
| Notes |
Study duration 2 years. Observer masked status is questionable because of miosis.
At baseline, 51 patients were excluded.
Drop‐outs during follow up: 18 timolol (4 adverse event or death) and 36 pilocarpine (7 adverse event or death). The authors do not state whether the adverse events or deaths were drug‐related. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
